Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genfit SA
Keeping Track Of Breakthroughs: AZ Farxiga, ImmunoGen ADC For Hematologic Cancer, Inventiva NASH Candidate Earn Designation
The latest breakthrough therapy designation news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
Akero gets FDA’s ok to conduct Phase IIb/III study of FGF21 analog efruxifermin in biopsy-confirmed non-alcoholic steatohepatitis patients. With NASH leadership up in the air, Akero, 89bio and other FGF analog sponsors jockey for top spot.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools